Delentin125 mg

Delentin is an anthelmintic (antiparasitic) agent indicated for the treatment of intestinal worm infections caused by susceptible organisms.

Established/Approved Uses

• Pinworm infection (Enterobiasis), caused by Enterobius vermicularis — a primary approved indication.
• Roundworm infection (Ascariasis), caused by Ascaris lumbricoides.
• Hookworm infection, caused by Ancylostoma duodenale and Necator americanus, particularly in mixed infections with pinworm or roundworm.

Guideline-Supported / Additional Uses

• Trichostrongylus infection in regions where this is prevalent.

Delentin is generally less effective against whipworm (Trichuris trichiura); combination or alternative therapy is usually needed if whipworm co-infection is confirmed, as advised by a physician.

Each 5 mL (one teaspoonful) of oral suspension typically contains Pyrantel Pamoate equivalent to 250 mg of pyrantel base (commonly formulated as 50 mg/mL pyrantel base). Tablet/chewable formulations may also be available in some markets. Strength and available dosage forms may vary by manufacturer; check the product label for exact composition.

Delentin is a broad-spectrum anthelmintic belonging to the tetrahydropyrimidine class, used for the treatment of common intestinal nematode (roundworm-type) infections. It works by paralyzing worms so they can be expelled from the body in the stool.

Because Delentin is poorly absorbed from the gastrointestinal tract, it acts primarily within the intestinal lumen, which limits systemic drug exposure while allowing the medication to act directly on the parasites present in the gut.

Delentin belongs to the anthelmintic (antiparasitic) therapeutic class, specifically the tetrahydropyrimidine group of depolarizing neuromuscular blocking anthelmintics.

Pyrantel Pamoate acts as a depolarizing neuromuscular blocking agent against susceptible intestinal nematodes. It causes persistent activation of nicotinic acetylcholine receptors on the worm's muscle cells, leading to sustained depolarization, spastic paralysis of the parasite's neuromuscular system, and release of its intestinal grip.

The paralyzed worms are then expelled from the body through normal bowel movements (peristalsis), without requiring a purgative. Pyrantel Pamoate is poorly absorbed from the gastrointestinal tract (roughly 7–15% systemic absorption), and the small fraction absorbed is partially metabolized in the liver and excreted mainly in urine and feces (largely as unchanged drug in feces).

Delentin oral suspension should be shaken well before each use. It can be taken orally at any time of day, with or without food, and may be mixed with milk or fruit juice. No fasting, purging, or laxative use is required before or after taking Delentin.

Delentin and piperazine (another anthelmintic) are mutually antagonistic in their mechanisms of action (one causes muscle paralysis by depolarization, the other by hyperpolarization) and should not be co-administered, as concurrent use may reduce the antiparasitic effectiveness of both drugs.

Limited data suggest a possible interaction with theophylline, with reports of increased theophylline blood levels when co-administered with Delentin; monitoring may be advised by a physician if concurrent use is necessary.

Always inform your physician or pharmacist about all medicines, supplements, or other anthelmintics being used before starting Delentin.

Delentin is generally well tolerated at recommended doses, as it is poorly absorbed systemically. Reported side effects are usually mild and transient.

Common

• Gastrointestinal upset: nausea, vomiting, abdominal cramps, diarrhea, anorexia
• Headache
• Dizziness

Uncommon

• Skin rash
• Drowsiness or insomnia
• Transient elevation of liver enzymes

These effects are typically mild and resolve without specific treatment. Consult a physician if side effects are severe or persistent.

Pregnancy: Adequate, well-controlled studies of Delentin in pregnant women are not available. As a general precaution with anthelmintics, Delentin should be used during pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus; treatment is often deferred until after delivery when possible unless the infection requires urgent treatment. Consult a physician before use.

Lactation: It is not well established whether Delentin or its metabolites pass into human breast milk. Because systemic absorption is low, risk to a nursing infant is thought to be limited, but caution is advised — consult a physician before use during breastfeeding.

Delentin should be used with caution in patients with significant hepatic (liver) impairment, as the small absorbed fraction of the drug undergoes hepatic metabolism; physician supervision is recommended in such patients.

Safety in children under 1–2 years of age has not been well established; use in this age group should be under medical supervision only (see Use in Special Populations).

Complete the full prescribed dosing regimen for Delentin, including any recommended repeat dose (e.g., after 2 weeks for pinworm), and treat household or close contacts simultaneously if advised by a physician, to reduce the risk of reinfection and further spread.

Do not co-administer with piperazine (see Drug Interactions).

General hygiene measures (handwashing, keeping fingernails short, washing bedding and clothing) are recommended alongside treatment with Delentin to help prevent reinfection, especially for pinworm.

Overdose with Delentin is likely to present as an exaggeration of common side effects, such as significant gastrointestinal upset (nausea, vomiting, diarrhea), dizziness, or headache. There is no specific antidote for Delentin overdose.

If an overdose of Delentin is suspected, seek immediate medical attention or contact a poison control center. Treatment is supportive and symptomatic; do not attempt specific home remedies without professional medical guidance.

Store at room temperature (below 30°C), away from light and moisture. Do not freeze. Keep out of reach of children.

Pediatric Use

Delentin is generally not recommended for children under 1–2 years of age, as safety and efficacy in this age group have not been well established; use should only be under direct medical supervision if considered necessary. For older infants and children, dosing is weight-based (11 mg/kg, maximum 1 g) — see Dosage and Administration.

Elderly

No specific dose adjustment is generally required in elderly patients, though caution is advised in those with hepatic impairment.

Hepatic Impairment

Delentin should be used with caution in patients with liver disease, under physician supervision (see Precautions and Warnings).

Renal Impairment

No specific dose adjustment is well established for renal impairment, as systemic absorption of Delentin is low; use with caution and physician guidance.

Treatment with Delentin is typically a single-dose regimen for pinworm and roundworm infections, sometimes with a repeat single dose after 2 weeks for pinworm. For heavier hookworm infections, treatment may extend to 2–3 consecutive daily doses, as directed by a physician.

Pyrantel Pamoate belongs to the tetrahydropyrimidine class of anthelmintics (depolarizing neuromuscular blocking agents).

Pyrantel Pamoate acts as a depolarizing neuromuscular blocking agent at the neuromuscular junction of susceptible nematodes, causing persistent stimulation of nicotinic acetylcholine receptors. This leads to spastic paralysis of the worm's musculature, causing it to lose its grip on the intestinal wall and be expelled naturally through peristalsis.

Delentin is used in children for the treatment of pinworm, roundworm, and hookworm infections, generally in children above 1–2 years of age, using the same weight-based dosing as adults (11 mg/kg, maximum 1 g single dose). Safety and efficacy in children under this age have not been well established, and use in very young children should be under direct medical supervision only. Accurate weight-based dosing using the oral suspension is recommended for pediatric patients (see Dosage and Administration).